8-Cyclopentyl-1-propyltheophylline | 152529-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-Cyclopentyl-1-propyltheophylline
• 英文别名: 8-cyclopentyl-1-propyl-3,7-dihydropurine-2,6-dione
• CAS: 152529-77-6
• 化学式: C₁₃H₁₈N₄O₂
• 分子量: 262.312
• InChiKey: CUGZRZZLABJZOU-UHFFFAOYSA-N

物化性质

• 密度：
  1.276±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  78.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-Cyclopentyl-1-propyltheophylline 在 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 (8-Cyclopentyl-7-methyl-2,6-dioxo-1-propylpurin-3-yl)methyl 2,2-dimethylpropanoate
  参考文献：
  名称：

  A₁ Adenosine Receptor Antagonists as Ligands for Positron Emission Tomography (PET) and Single-Photon Emission Tomography (SPET)

  摘要：

  The high affinity of 8-cyclopentyl-1,3-dipropylxanthine (CPX) for the A(1) adenosine receptor (A(1)AR) provides a good lead for developing radioligands suitable for positron emission tomography (PET) and single-photon emission tomography (SPET). This study tested the hypothesis that the kinds of chemical modifications made in the synthesis of CPX analogues containing carbon-ii, fluorine-18, or radioiodine will not alter affinity for the A(1)AR. This report describes the synthesis and radioligand binding assays of unlabeled CPX analogues having methyl, 2-methoxyethyl, 2-fluoropropyl, or 3-fluoropropyl substituents, respectively, at either N-1 (13a-d) or N-3 (8a-d) or an (E)-3-iodoprop-2-en-1-yl substituent at N-3 (8f). Compounds 8d,f and 13b,d antagonized the binding of [H-3]CPX to the A(1)AR of rat brain with affinities similar to those of CPX; compound 8c was twice as potent as CPX. Analogues 8a,b and 13a were less potent than CPX, but for each the K-i of antagonism was greater than or equal to 0.5 nM. Attempts to iodinate the 8-(4-hydroxyphenyl) analogue of CPX failed, probably because the xanthine substituent strongly deactivated the phenol toward electrophilic iodination. In summary, several of the modifications of the propyl groups of CPX needed to produce ligands for imaging by PET and SPET preserve or enhance affinity for the A(1)AR.

  DOI：

  10.1021/jm9705465
• 作为产物：
  描述：

  环戊酸 在 1-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride 、 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 8-Cyclopentyl-1-propyltheophylline
  参考文献：
  名称：

  对位黄嘌呤类似物（1,7-二取代的黄嘌呤）和其他在3位未取代的黄嘌呤的合成：腺苷受体的结构活性关系。

  摘要：

  开发了用于制备各种3-未取代的黄嘌呤的合成方法，包括对黄嘌呤类似物（1,7-二取代的黄嘌呤）和1,8-二取代的黄嘌呤。1-取代的黄嘌呤的甲硅烷基化，然后在7-位的烷基化提供了一种简便的途径生产对黄嘌呤类似物。三（三甲基甲硅烷基）-6-氨基尿嘧啶的区域选择性烷基化提供了3-取代的6-氨基尿嘧啶，其通过标准方法转化为1,8-二取代的黄嘌呤。3-取代的5-环戊烷羧酰胺基和5-（苯甲酰基氨基）-6-氨基尿嘧啶的闭环需要剧烈的反应条件。在这些和其他具有1、3、7、8和9位取代基的黄嘌呤的结合测定中，确定了对大脑A1和A2腺苷受体的亲和力。为了在腺苷受体上具有高亲和力，必须在1位进行取代。1，3-二取代的黄嘌呤通常比1，7-二取代的黄嘌呤具有更高的亲和力。1,8-二取代的黄嘌呤对腺苷受体具有高亲和力。一些对A1受体具有高度选择性。

  DOI：

  10.1021/jm00074a015

文献信息

• Pharmaceutical formulations comprising substituted xanthine compounds
  申请人：Rudolph R Alfred

  公开号：US20060052404A1

  公开（公告）日：2006-03-09

  The present invention provides novel pharmaceutical compositions comprising substituted xanthine compounds useful for the treatment of cystic fibrosis and other diseases, and methods of use thereof.
• [EN] ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY<br/>[FR] ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE PRESENTANT UNE BIOACTIVITE AMELIOREE
  申请人：UNIVERSITY OF SOUTH FLORIDA

  公开号：WO1999031101A1

  公开（公告）日：1999-06-24

  (EN) Xanthine A1AR antagonist having halogenated N-1 and/or N-3 side chains are provided. The methods for the syntheses of such antagonists are also provided. The methods for using such antagonist labeled with carbon-11, fluorine-18 or isotopes of iodine such as iodine-123 for medical diagnostic imaging of the A1AR in patients are provided. Methods for improving the potency and duration of action of xanthine A1AR antagonist by halogenation of N-1 and N-3 propyl substituents is provided.(FR) L'invention concerne une xanthine, antagoniste du récepteur de l'adénosine A1, et/ou des chaînes latérales de N-3. L'invention traite également de procédés permettant d'effectuer la synthèse de ces antagonistes. L'invention a aussi pour objet des procédés permettant d'utiliser cet antagoniste marqué au carbone-11, au fluor-18 ou des isotopes d'iode tel que l'iode-123 pour l'imagerie diagnostique médicale du récepteur de l'adénosine A1 chez les patients. L'invention traite aussi de procédés permettant d'améliorer la puissance et la durée d'action de la xanthine, antagoniste du récepteur de l'adénosine A1 par halogénation de substituants de propyle N-1 et N-3.
• Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors
  作者：Christa E. Mueller、Dan Shi、Malcolm Manning、John W. Daly

  DOI：10.1021/jm00074a015

  日期：1993.10

  paraxanthine analogs (1,7-disubstituted xanthines) and 1,8-disubstituted xanthines, were developed. Silylation of 1-substituted xanthines followed by alkylation at the 7-position provides a facile route to paraxanthine analogs. Regioselective alkylation of tris(trimethylsilyl)-6-aminouracil provides 3-substituted 6-aminouracils, which are converted to 1,8-disubstituted xanthines by standard procedures

  开发了用于制备各种3-未取代的黄嘌呤的合成方法，包括对黄嘌呤类似物（1,7-二取代的黄嘌呤）和1,8-二取代的黄嘌呤。1-取代的黄嘌呤的甲硅烷基化，然后在7-位的烷基化提供了一种简便的途径生产对黄嘌呤类似物。三（三甲基甲硅烷基）-6-氨基尿嘧啶的区域选择性烷基化提供了3-取代的6-氨基尿嘧啶，其通过标准方法转化为1,8-二取代的黄嘌呤。3-取代的5-环戊烷羧酰胺基和5-（苯甲酰基氨基）-6-氨基尿嘧啶的闭环需要剧烈的反应条件。在这些和其他具有1、3、7、8和9位取代基的黄嘌呤的结合测定中，确定了对大脑A1和A2腺苷受体的亲和力。为了在腺苷受体上具有高亲和力，必须在1位进行取代。1，3-二取代的黄嘌呤通常比1，7-二取代的黄嘌呤具有更高的亲和力。1,8-二取代的黄嘌呤对腺苷受体具有高亲和力。一些对A1受体具有高度选择性。
• A₁ Adenosine Receptor Antagonists as Ligands for Positron Emission Tomography (PET) and Single-Photon Emission Tomography (SPET)
  作者：Marcus H. Holschbach、Thomas Fein、Christof Krummeich、Robert G. Lewis、Walter Wutz、Ulrich Schwabe、Dieter Unterlugauer、Ray A. Olsson

  DOI：10.1021/jm9705465

  日期：1998.2.1

  The high affinity of 8-cyclopentyl-1,3-dipropylxanthine (CPX) for the A(1) adenosine receptor (A(1)AR) provides a good lead for developing radioligands suitable for positron emission tomography (PET) and single-photon emission tomography (SPET). This study tested the hypothesis that the kinds of chemical modifications made in the synthesis of CPX analogues containing carbon-ii, fluorine-18, or radioiodine will not alter affinity for the A(1)AR. This report describes the synthesis and radioligand binding assays of unlabeled CPX analogues having methyl, 2-methoxyethyl, 2-fluoropropyl, or 3-fluoropropyl substituents, respectively, at either N-1 (13a-d) or N-3 (8a-d) or an (E)-3-iodoprop-2-en-1-yl substituent at N-3 (8f). Compounds 8d,f and 13b,d antagonized the binding of [H-3]CPX to the A(1)AR of rat brain with affinities similar to those of CPX; compound 8c was twice as potent as CPX. Analogues 8a,b and 13a were less potent than CPX, but for each the K-i of antagonism was greater than or equal to 0.5 nM. Attempts to iodinate the 8-(4-hydroxyphenyl) analogue of CPX failed, probably because the xanthine substituent strongly deactivated the phenol toward electrophilic iodination. In summary, several of the modifications of the propyl groups of CPX needed to produce ligands for imaging by PET and SPET preserve or enhance affinity for the A(1)AR.